Outlook Therapeutics(OTLK) - 2024 Q4 - Annual Results

Exhibit 99.1 Outlook TherapeuticsReports Financial Results for Fiscal Year 2024 and Provides Corporate Update · LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25 · Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., December 27, 2024 — (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biop ...